Linz Researchers Say 454 Sequencing Will Improve Tissue Matching for Transplants | GenomeWeb
Researchers at the Blood Center Linz in Austria are betting on second-generation sequencing technology to improve tissue matching between donors and bone marrow or stem-cell transplant patients.
 
The researchers, who acquired a 454 Genome Sequencer FLX in May, said they eventually want to develop a sequencing method for routine use in HLA typing, which they say would be one of the first applications of 454’s technology in medical care.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.